[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Hara I, Hikosaka S, Eto H, Miyake H, Yamada Y, Soejima T, Sugimura K, Kamidono S: Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. Int J Urol; 2004 Aug;11(8):678-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy.
  • We report on two cases of women with locally advanced squamous cell carcinoma of the urethra.
  • Treatment comprised combined radiotherapy to 60 Gy and chemotherapy with 5-fluorouracil and cisplatin.
  • Patient 1 experienced recurrent inguinal lymph node metastasis on the contralateral side at 42 months after initial treatment, and the same treatment was performed followed by surgical excision.
  • Both patients remain alive with no evidence of disease, at 12 months after recurrence in Patient 1, and at 27 months after treatment in Patient 2.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285764.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 9
  •  go-up   go-down


2. Koizumi T, Bando S, Kanda K, Inai T: [Two cases of primary female urethral cancer]. Nihon Hinyokika Gakkai Zasshi; 2007 Sep;98(6):790-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of primary female urethral cancer].
  • Herein, we report two cases of female urethral cancer.
  • Magnetic resonance imaging (MRI) revealed a urethral tumor in both cases.
  • Histopathological examination of transperineal biopsy specimens from both patients suggested clear cell adenocarcinoma in case 1 and squamous cell carcinoma in case 2.
  • With reference to case 1, obturator lymph node metastases were observed during surgery, and treatment comprised combined radiotherapy to 60 Gy and chemotherapy with 5-fluorouracil and cisplatin following surgery.
  • However, metastases appeared in the lung 6 months after initial treatment and she died 20 months after surgery.
  • The same combined treatment was performed and a complete response was obtained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Urethral cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929463.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


3. Smith Y, Hadway P, Ahmed S, Perry MJ, Corbishley CM, Watkin NA: Penile-preserving surgery for male distal urethral carcinoma. BJU Int; 2007 Jul;100(1):82-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile-preserving surgery for male distal urethral carcinoma.
  • OBJECTIVE: To evaluate medium-term outcome data from patients with distal urethral cancers treated with penile-preserving surgery.
  • PATIENTS AND METHODS: We analysed prospectively 18 consecutive men referred for the management of urethral carcinoma.
  • Tumours were staged according to the Tumour-Node-Metastasis classification and the patients offered penile-preserving surgery when tumours were limited to the glanular or penile urethra.
  • RESULTS: All 18 patients were suitable for penile-preserving surgery; the procedures were: three hypospadias formation with or without topical chemotherapy; four buccal mucosa urethroplasty; three glansectomy and reconstruction; six glansectomy, distal corporectomy, reconstruction and hypospadias formation; two urethrectomy with or with no excision of adjacent tunica albuginea.
  • CONCLUSION: Medium-term data show that penile-preserving surgery is a feasible treatment for men with distal urethral carcinoma, providing excellent local control without prejudicing survival; a longer follow-up is needed.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Penis / surgery. Urethral Neoplasms / surgery. Urologic Surgical Procedures, Male / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488307.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Magnetic resonance imaging showed a tumor surrounding the urethra, which invaded to the vesical triangle and the anterior vaginal wall.
  • Serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9 were elevated, but squamous cell carcinoma antigen and prostate specific antigen were within normal limits.
  • First, the patient received local chemoradiotherapy and systemic chemotherapy using a fluoropyrimidine drug TS-1 and cisplatin.
  • The tumor markers declined to within normal limits after this preoperative therapy.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Goto T, Noguchi A, Hamamoto Y, Minoshima K, Taniguchi M, Takeuchi T, Sakai S, Iwata H, Sasaoka I: [Primary squamous cell carcinoma of the prostate forming a rectourethral fistula: a case report]. Hinyokika Kiyo; 2001 Jun;47(6):433-6
MedlinePlus Health Information. consumer health - Urethral Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary squamous cell carcinoma of the prostate forming a rectourethral fistula: a case report].
  • Eleven cases of squamous cell carcinoma of the prostate have been previously reported in the Japanese medical literature.
  • Patients with this type of carcinoma have dismal prognoses.
  • A transrectal needle biopsy was performed, and histology of the tissue showed squamous cell carcinoma.
  • After chemotherapy using methotrexate, pirarubicin, and cisplatin, total pelvic excentration was performed.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Intestinal Fistula / complications. Prostatic Neoplasms / complications. Rectal Diseases / complications. Serpins. Urethral Diseases / complications. Urinary Fistula / complications
  • [MeSH-minor] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Combined Modality Therapy. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496402.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  • [Number-of-references] 19
  •  go-up   go-down


6. Yoshinaga A, Hayashi T, Ishii N, Ohno R, Terao T, Kamata S, Watanabe T, Yamada T: [Vesicorectal fistula caused by pelvic metastasis of penile cancer: a case report]. Hinyokika Kiyo; 2005 Jan;51(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor biopsy revealed squamous cell carcinoma.
  • Although he was given radiation therapy and subcutaneous injection therapy of bleomycin, viable cancer cells remained.
  • Then he was given combination chemotherapy of bleomycin and cisplatin, and paint therapy of bleomycin ointment.
  • Local recurrence with a cauliflower-like tumor occurred five years after the chemotherapy.
  • Computerized tomography of pelvis demonstrated a mass 3 cm in diameter in the anterior portion of anal and cystogram demonstrated a vesicorectal fistula.
  • Then we inserted a urethral catheter, which resulted in obstruction of fistula by its balloon, and we made a cystostomy for securing urinary tract.
  • Pathological examination of tissue around the fistula revealed squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Pelvic Neoplasms / secondary. Penile Neoplasms / pathology. Rectal Fistula / etiology. Urinary Bladder Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732344.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Buechner SA: Common skin disorders of the penis. BJU Int; 2002 Sep;90(5):498-506
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review highlights the clinical features, diagnosis and treatment of the most common dermatoses of the male genitalia.
  • The most common causal agents for condyloma acuminatum are low-risk HPV 6 and 11; high-risk HPV types 16 and 18 are associated with premalignant and malignant lesions.
  • Treatment for genital warts remains unsatisfactory; recurrences are common.
  • Imiquimod, a new topical immunotherapeutic agent, which induces interferon and other cytokines, has the potential to be a first-line therapy for genital warts.
  • Oral ivermectin, a highly active antiparasitic drug, is likely to be the treatment of choice, but until approval is granted it should be reserved for special forms of scabies.
  • The penile form is a common cause of phimosis in uncircumcised men; involvement of the urethral meatus may lead to progressive meatal stenosis.
  • Plasma cell balanitis is a benign, idiopathic condition presenting as a solitary, smooth, shiny, red-orange plaque of the glans and prepuce of a middle-aged to older man.
  • Squamous cell carcinoma (SCC) in situ, e.g. erythroplasia of Queyrat and Bowen's disease, cannot be excluded clinically; their apparent clinical benignity may lead to lengthy periods of misdiagnosis and biopsy is required to confirm the diagnosis.
  • SCC is the most common malignancy of the penis and the role of oncogenic HPV-types has been also established in SCC of the penis.
  • Prevention of SCC of the penis presupposes an identification of risk factors, early detection of all pre-cancerous lesions and treatment of phimosis.
  • [MeSH-minor] Balanitis / diagnosis. Balanitis / therapy. Humans. Male. Mite Infestations / diagnosis. Mite Infestations / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Skin Diseases, Parasitic / diagnosis. Skin Diseases, Parasitic / therapy. Skin Diseases, Viral / diagnosis. Skin Diseases, Viral / therapy

  • MedlinePlus Health Information. consumer health - Penis Disorders.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12175386.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 39
  •  go-up   go-down


8. Hettiarachchi JA, Johnson GB, Panageas E, Drinis S, Konno S, Das AK: Malignant priapism associated with metastatic urethral carcinoma. Urol Int; 2001;66(2):114-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant priapism associated with metastatic urethral carcinoma.
  • We present a 40-year-old man with malignant priapism secondary to urethral squamous cell carcinoma.
  • Magnetic resonance imaging revealed the tumor originating from the bulbous urethra, extending into the penile urethra and corpora spongiosa and cavernosa.
  • A penile biopsy confirmed poorly differentiated squamous cell carcinoma of the urethra.
  • Despite administration of systemic chemotherapy, the prognosis of the patient has worsened due to the extensive metastatic disease.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / secondary. Priapism / etiology. Urethral Neoplasms / complications. Urethral Neoplasms / secondary

  • Genetic Alliance. consumer health - Priapism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11223757.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Lee DJ, Rothberg MB, McKiernan JM, Benson MC, Badani KK: Robot-assisted radical cystoprostatectomy in complex surgical patients: single institution report. Can J Urol; 2009 Jun;16(3):4664-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and feasibility of robotic-assisted radical cystoprostatectomy (RRCP) in a salvage setting for patients with a history of radiation and chemotherapy treatment, complex pelvic anatomy, and significant comorbidities.
  • MATERIALS AND METHODS: Over a 5 month period, six patients who met these criteria underwent RRCP for urothelial carcinoma.
  • Two of the patients had major cardiovascular disease and were previously denied an open procedure subsequently underwent chemotherapy with external beam radiation protocol.
  • One patient had brachytherapy for prior prostate cancer, and three additional patients had neoadjuvant chemotherapy with large diverticula, measuring up to 12 cm in size.
  • Four patients had pathologic pT3a disease, one patient had pT4a, and one patient had pT1 urethral squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Prostatectomy / methods. Robotics. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Salvage Therapy. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2009 Jun;16(3):4670 [19497176.001]
  • (PMID = 19497175.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


10. Trabulsi EJ, Hoffman-Censits J: Chemotherapy for penile and urethral carcinoma. Urol Clin North Am; 2010 Aug;37(3):467-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for penile and urethral carcinoma.
  • Although surgery is the mainstay of curative treatment of carcinomas of the penis and urethra, there is a role for systemic cytotoxic chemotherapy for locally advanced, unresectable, or metastatic tumors.
  • Although this field is limited by a paucity of clinical trials or prospective data, the available single institutional retrospective reviews indicate that multi-agent cisplatin-based combination chemotherapy regimens have significant activity and may allow curative surgery for patients with otherwise unresectable tumors.
  • This article reviews the available literature on chemotherapy for carcinoma of the penis and urethra in the neoadjuvant, adjuvant, and metastatic setting.
  • [MeSH-major] Penile Neoplasms / drug therapy. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Chemotherapy, Adjuvant. Humans. Male. Neoadjuvant Therapy. Taxoids / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674701.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids
  • [Number-of-references] 34
  •  go-up   go-down


11. Tazi K, Moudouni S, Karmouni T, Koutani A, Hachimi M, Lakrissa A: [Epidermoid carcinoma of the male urethra]. Prog Urol; 2000 Sep;10(4):600-2
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinoma of the male urethra].
  • Squamous cell carcinoma of the male urethra is exceptional, as all urethral tumours represent less than 1% of urinary tract tumours.
  • Treatment depends on the stage and site of the lesion, but the prognosis remains very poor despite aggressive treatment, including mutilating resection surgery with or without associated radiotherapy.
  • However, the current hope for patients with squamous cell carcinoma of the urethra resides in radiotherapy-chemotherapy combination protocols based on the results obtained in squamous cell cancers of the oesophagus and anus.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Urethral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064906.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 15
  •  go-up   go-down


12. Hakenberg OW, Franke HJ, Froehner M, Wirth MP: The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy. Onkologie; 2001 Feb;24(1):48-52
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy.
  • BACKGROUND: Primary urethral carcinoma is a very rare condition, and no large-scale experience with such cases has been published.
  • Treatment will therefore have to follow rules established for the treatment of similar conditions.
  • PATIENTS: Six cases of primary urethral carcinoma (5 male, 1 female) who had been treated at our institution between 1995 and 1999 were retrospectively analyzed.
  • In 3 male cases, a primary urothelial carcinoma of the distal urethra was treated by distal urethrectomy only.
  • In 3 other cases with locally advanced tumors and/or lymph node metastases surgical treatment was followed by adjuvant cisplatinum-containing chemotherapy.
  • RESULTS: In the 3 cases with distal urethral carcinoma, partial urethrectomy with preservation of the penis resulted in cure, with a follow-up of 12-71 months.
  • In the cases with advanced disease, adjuvant chemotherapy after surgery has resulted in complete remissions in all 3 cases, with a follow-up of 4-47 months at present.
  • CONCLUSIONS: In localized, noninvasive carcinoma of the distal male urethra, partial urethrectomy seems adequate and the avoidance of penile amputation justified.
  • In advanced cases, after local excision and lymphadenectomy adjuvant chemotherapy which by necessity must follow the guidelines established for the treatment of other urothelial or squamous cell malignancies seems to be beneficial.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441281.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Sopena JM, González JA, Queralt MP, Sariol JC, Redorta JP, Mavrich HV: [Metastasic urethral squamous-cell a cancer]. Actas Urol Esp; 2009 Jun;33(6):712-6
Genetic Alliance. consumer health - Urethral cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasic urethral squamous-cell a cancer].
  • [Transliterated title] Carcinoma escamoso de uretra metastático.
  • Urethral cancer is an infrequent pathology, less than 1% of the genitourinary tumors.
  • The most frequent histology being squamous cell carcinoma.
  • The interval between the onset of symptoms and diagnosis may be as long as three years.
  • Therefore most of these tumors are locally advanced at the time of diagnosis with generally poor prognosis despite aggressive treatment.
  • Therapeutic management varies with the stage and location of the lesion.
  • Because of the rarity of this pathology, no consensus has been reached on treatment modalities, but seems to be that must be a multimodal one, including surgery, radiotherapy and chemotherapy.
  • We present the case of an 80 year-old male, with a diagnosis of urethral squamous-cell cancer, locally advanced at the time of diagnosis.
  • The patient underwent chemotherapy and radiotherapy with evidence of quick progression thereafter.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Urethral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711759.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Osai WE, Ng CS, Pagliaro LC: Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs; 2008 Apr;19(4):427-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma.
  • We report the case of a 78-year-old man with metastatic transitional-cell carcinoma with squamous differentiation that responded dramatically to the monoclonal antibody agent, bevacizumab.
  • The tumor originated in the bulbar urethra, with histology of poorly differentiated urothelial carcinoma.
  • Metastasis to a right inguinal lymph node was biopsy-confirmed as transitional-cell carcinoma with areas of keratinization.
  • At last follow-up, he had received 24 months of bevacizumab treatment with minimal toxicity and a positive response.
  • Mediators of angiogenesis have been implicated in the clinical progression of bladder cancer, although the role of angiogenesis inhibitors as treatment has not yet been defined.
  • The striking benefit achieved in this heavily treated patient suggests that bevacizumab could have clinically useful antitumor activity in advanced urothelial carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Drug Resistance, Neoplasm. Urethral Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454053.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


15. Nicholson S, Tsang D, Summerton D: Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra. Nat Clin Pract Urol; 2008 Oct;5(10):574-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra.
  • INVESTIGATIONS: Pelvic examination under anesthetic by both a urologist and gynecologist, biopsy of the urethral tumor and of the cervix, pathological analysis, MRI of the pelvis, CT of the chest, abdomen and pelvis.
  • DIAGNOSIS: Poorly differentiated squamous cell carcinoma of the urethra, T4N0M0.
  • MANAGEMENT: The patient received two cycles of neoadjuvant TIP (paclitaxel, ifosfamide, cisplatin) chemotherapy, resulting in complete remission, followed by consolidative chemoradiation therapy (radiation therapy given with synchronous weekly cisplatin).
  • She remained relapse-free 48 months after diagnosis, with normal voiding and sexual function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762780.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL: Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum; 2001 Apr;44(4):506-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome analysis of HIV-positive patients with anal squamous cell carcinoma.
  • PURPOSE: With improved antiretroviral therapy, HIV-positive patients are achieving a longer life expectancy.
  • An increased incidence of anal squamous cell carcinomas has been noted in these patients.
  • The purpose of this study was to determine the outcome of HIV-positive patients with anal squamous cell carcinomas.
  • We identified 73 patients with anal squamous cell carcinoma treated at the University of Texas Southwestern Medical Center affiliated hospitals; 23 were HIV positive (18 had AIDS).
  • In the HIV-positive group, 9 had in situ squamous carcinomas and 14 had invasive squamous cell carcinomas.
  • Data collected included age, CD4 count, treatment, complications, and survival; these data were analyzed by Student's t-test.
  • Those with squamous cell cancer of the anus were offered radiation therapy and chemotherapy.
  • Beginning in 1998, all patients received highly active antiretroviral therapy before treatment.
  • Seven of 14 anal squamous cell carcinoma patients had their therapy adjusted owing to toxicity.
  • Morbidity included proctocolitis and diarrhea (n = 2) requiring diversion (n = 1), hemorrhagic cystitis (n = 1), neutropenic fever (n = 3), bone marrow suppression (n = 1), and urethral stricture (n = 1).
  • Mean age was 42 years for anal squamous cell carcinoma patients and 36 years for squamous cell carcinoma in situ patients (P = 0.05).
  • Mean CD4 count was 222 cells/ml in patients with infiltrating carcinoma and 200 in the in situ patients (P = NS).
  • One-year and five-year mortality rates, respectively, were 40 percent and 80 percent for infiltrating carcinoma patients and 17 percent and 50 percent for the in situ patients.
  • Both of the in situ patients who died had CD4 counts <20 cells/ml at diagnosis, whereas the rest had CD4 counts >100 cells/ml and are currently without anal disease.
  • Mean CD4 count at diagnosis for all patients who died was 133 cells/ml, whereas for those surviving, it was 261 cells/ml (P = 0.03).
  • Eight (all with infiltrating carcinoma) of the 10 patients who died had persistent anal disease, but none had metastasis.
  • A low CD4 count at diagnosis without highly active antiretroviral therapy predicts a poor prognosis.
  • Because these patients appear to succumb to their HIV status and not the anal disease, anal squamous cell carcinoma should be included with cervical squamous cell carcinoma as an AIDS-defining illness.
  • HIV-positive patients, particularly AIDS patients, with invasive anal cancers and without effective antiretroviral therapy obtain little benefit and significant toxicity from current radiation therapy and chemotherapy.
  • Initiation of highly active antiretroviral therapy in HIV-positive patients before radiation therapy and chemotherapy are begun may decrease toxicity and improve survival.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma in Situ / complications. Carcinoma, Squamous Cell / complications. HIV Infections / complications
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Combined Modality Therapy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome


17. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • We reviewed 53 patients (mean age 63 years) who underwent partial urethrectomy (n = 26) or radical extirpation (n = 27) for primary female urethral cancer from 1948 through 1999.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • The predominant carcinomas were squamous cell (n = 21), transitional cell (TCC) (n = 15), and adenocarcinoma (n = 14).
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • Of patients undergoing partial urethrectomy for pT1-3 tumors, 6/27 (22%) had urethral recurrence.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jin B, Pickens A, Shah MB, Turrisi A, Saleh H: Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case. Diagn Cytopathol; 2010 Dec;38(12):925-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case.
  • Squamous carcinoma is the most common malignancy of the vagina.
  • Other malignancies include adenocarcinoma, melanoma, lymphoma, and very rarely, neuroendocrine carcinoma/small-cell carcinoma.
  • Large cell neuroendocrine carcinoma (LCNEC) has not been reported in this location.
  • Thin prep of vaginal swap was interpreted as atypical glandular cells; however, the biopsies showed a large cell neuroendocrine carcinoma which was confirmed by diffuse strong immunoreactivity to AE1/3, CAM5.2, CK7, and CD56 in the tumor cells.
  • Subsequent clinical workup showed that the patient also had numerous metastatic nodules in the bilateral lungs and a vaginal-urethral fistula caused by the tumor.
  • The patient underwent palliative radiation of pelvis for local pain control and then chemotherapy.
  • Although the vaginal tumor increased in size even after radiation, her symptoms were under control and she was doing well for a short period of time.
  • The patient is still alive but developed brain metastasis a year later after initial diagnosis.
  • Despite its rarity, large cell neuroendocrine cell carcinoma should be included in the differential diagnosis when cytomorphology shows features suggestive of neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Antigens, CD56 / metabolism. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20222107.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


19. Cetina L, Rivera L, Candelaria M, de la Garza J, Dueñas-González A: Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs; 2004 Sep;15(8):761-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response, toxicity and renal function pre- and post-therapy were evaluated.
  • Pre-treatment serum creatinine ranged from 1.6 to 18.5 mg/100 ml (median 3.3, mean 6.8) and creatinine clearance varied from 4 to 57 mg/ml/min (median 17, mean 22.1).
  • All patients had improvement in creatinine clearance (pre-therapy 22.78, post-therapy 54.3 mg/ml/min) (p=0.0058) and all but one normalized serum creatinine.
  • In this setting where cisplatin-based therapy is contraindicated, the use of gemcitabine may be considered.
  • [MeSH-major] Chemotherapy, Adjuvant / methods. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Radiotherapy, Adjuvant / methods. Renal Insufficiency / drug therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Brachytherapy / methods. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Creatinine / blood. Drug Administration Schedule. Drug Evaluation / methods. Female. Follow-Up Studies. Humans. Injections, Intravenous. Kidney Function Tests / methods. Mexico. Middle Aged. Neoplasm Staging. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Time Factors. Treatment Outcome. Urethral Obstruction / complications

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494637.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; AYI8EX34EU / Creatinine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Das S, Tunuguntla HS: Balanitis xerotica obliterans--a review. World J Urol; 2000 Dec;18(6):382-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many cases of BXO occurring after circumcision may be cases of secondary phimosis due to BXO not being recognized at the time of surgery.
  • Early diagnosis and treatment of BXO are very important in preventing the urological complications of the diseases such as urethral stricture.
  • Treatment of BXO depends on the anatomic location of the lesions and their extent and severity, together with the rapidity of progression of the disease process.
  • The treatment may vary from topical corticosteroids, laser vaporization in early cases to meatoplasty and urethroplasty in extensive cases.
  • Topical pharmacotherapy is useful in the early stages to reduce the initial symptoms and slow down the progression, but is not effective in all cases and is not the curative treatment of disease.
  • Meatal stenosis, phimosis, scar adhesions, fissures, erosions of glans and prepuce and involvement of the urethra are indications for surgical treatment.
  • Surgery seems to be the only treatment that can relieve the symptoms of advanced disease.
  • BXO involving anterior urethra can be treated by 2-stage urethroplasty or substitution urethroplasty.
  • The complete excision of the stricture and flap urethroplasty seems to be better than a 2-stage procedure.
  • However, at the present time, it is not possible to say that surgery can completely resolve this chronic and progressive disease.
  • Despite many reports in the literature of cases of BXO associated with squamous cell carcinoma, the etiologic relationship between the two conditions is uncertain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11204255.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 27
  •  go-up   go-down


21. Tsukamoto T, Yonese J, Kin T, Samejima T, Hasegawa Y, Fukui I, Ishikawa Y: [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment]. Nihon Hinyokika Gakkai Zasshi; 2002 Mar;93(3):483-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment].
  • Laser treatment is considered to be effective in treating carcinoma in situ of the penis.
  • We, however, report a case with carcinoma in situ of the penis which developed invasive carcinoma and inguinal lymphnode metastases only 6 months after the laser treatment.
  • A physical examination revealed thick erythema, 12 millimeters in diameter, around the external urethral meatus.
  • Histologically, biopsy revealed squamous cell carcinoma in situ.
  • Although the lesion appeared to slightly extend into the urethra, it was primarily treated with the CO2 laser.
  • Six months after the treatment, however, local recurrence was confirmed by the touch smear cytology, resulting in the partial amputation of the penis.
  • The histopathological examination revealed subepithelial and marked lymphatic invasion of the tumor and positive margin in the urethral stump (squamous cell carcinoma in situ).
  • The patient received adjuvant chemotherapy and has been alive and well without evidence of disease 40 months after the initial treatment.
  • [MeSH-major] Carcinoma in Situ / pathology. Lasers / adverse effects. Penile Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968805.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Negro CL, De Stefanis P, Bosio A, Bisconti A, De Maria C, Charchedi M, Buffardi A, Rolle L, Fontana D: [Transvaginal repair of neobladder vaginal fistula]. Urologia; 2010 Jan-Mar;77 Suppl 16:11-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive pathological examination revealed pT3aN0G3 urothelial cancer with squamous aspects.
  • Two cycles of neoadjuvant chemotherapy were administered before cystectomy.
  • At first, the patient was treated conservatively, keeping the urethral catheter for two months.
  • In our case, we performed a transvaginal approach without tissue interposition, with good results.
  • Such procedure is easy and effective and, in our opinion, can be tempted as first line surgical treatment.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Hysterectomy, Vaginal. Middle Aged. Radiography. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104654.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Gillitzer R, Hampel C, Wiesner C, Hadaschik B, Thüroff J: Single-institution experience with primary tumours of the male urethra. BJU Int; 2008 Apr;101(8):964-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution experience with primary tumours of the male urethra.
  • OBJECTIVE: To assess primary tumours of the urethra in males.
  • PATIENTS AND METHODS: We retrospectively reviewed our database from 1986 to 2006 for primary tumours of the male urethra; nine patients with primary tumours of the urethra were analysed and follow-up information was obtained.
  • RESULTS: Three patients had tumours of the prostatic urethra, two of which had proliferating focal inflammation and one a low-grade, superficial urothelial cancer.
  • Six patients had carcinoma of the bulbar or penile urethra, including two with previous local percutaneous radiotherapy for prostate cancer.
  • One patient had adjuvant chemotherapy after surgery.
  • CONCLUSION: Primary carcinoma of the male urethra is a rare entity.
  • Multimodal therapy might be required to obtain an optimum oncological outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Gómez Díaz ME, Castaño González-Coto D, Cuervo Calvo J, Muruamendiaraz Fernández V: [Cancer of the female urethra. Report of a new case a review of the literature]. Arch Esp Urol; 2002 Jun;55(5):568-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the female urethra. Report of a new case a review of the literature].
  • OBJECTIVE: To review the main features of female urethral cancer, the only genitourinary neoplasm with a predilection for women, the ratio being 4:1.
  • Female urethral cancer is an uncommon neoplasm that accounts for only 0.02% of all cancers found in women.
  • METHODS: A case of female urethral cancer in a 52-year-old woman is presented.
  • RESULTS/CONCLUSIONS: Female urethral cancer is an uncommon neoplasm.
  • For patients with Ta-2N0M0 tumors, multimodality therapy may not be required.
  • For patients with T3-4N0M0 tumors, the best results are obtained with multimodal radiation and chemotherapy with surgical resection.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174428.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


25. Lee KC: Carcinoma of the female urethra responsive to moderate dose chemoradiotherapy. J Urol; 2000 Mar;163(3):905-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the female urethra responsive to moderate dose chemoradiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10688008.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement